GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (LTS:0IHV) » Definitions » Institutional Ownership

Enzo Biochem (LTS:0IHV) Institutional Ownership : 7.02% (As of Apr. 24, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Enzo Biochem Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Enzo Biochem's institutional ownership is 7.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Enzo Biochem's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Enzo Biochem's Float Percentage Of Total Shares Outstanding is 89.46%.


Enzo Biochem Institutional Ownership Historical Data

The historical data trend for Enzo Biochem's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Institutional Ownership Chart

Enzo Biochem Historical Data

The historical data trend for Enzo Biochem can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 7.55 7.55 7.56 7.70 7.44 7.44 7.40 7.19 7.12 7.02

Enzo Biochem Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Enzo Biochem Business Description

Traded in Other Exchanges
Address
21 Executive Boulevard, Farmingdale, NY, USA, 11735
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.

Enzo Biochem Headlines

No Headlines